PNC Financial Services Group’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRS
BCM
PNC Financial Services Group's ACRS Position: Q3 2026 in Review
PNC Financial Services Group increased its Aclaris Therapeutics (ACRS) stake by 18% in Q3 2026, buying an estimated $2.11K and bringing the position to 2,434 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4025.
PNC Financial Services Group first reported a position in ACRS in Q4 2016 and has held it in 21 quarters since. The position peaked at $125K in Q2 2017. 167 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.
- PNC Financial Services Group held 2,434 shares of Aclaris Therapeutics worth $12.8K as of Q3 2026.
- PNC Financial Services Group bought 369 Aclaris Therapeutics shares in Q3 2026, an estimated $2.11K.
- Aclaris Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #4025 holding.
- PNC Financial Services Group first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 21 quarters since.
- PNC Financial Services Group's Aclaris Therapeutics position peaked at $125K in Q2 2017.
- 167 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.
Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.